FDA Halts uniQure's Huntington's Therapy, Demands Rigorous New Trial

LEXINGTON, Mass. and AMSTERDAM – March 02, 2026 – Hopes for an accelerated path to market for a promising Huntington's disease gene therapy were dashed today after uniQure N.V. announced a significant regulatory setback. The U.S. Food and Drug Administration (FDA) has informed the company that its existing data for AMT-130 is insufficient to support a marketing application, recommending a new, far more rigorous clinical trial. The news sent the company's stock (NASDAQ: QURE) plunging over 40% in premarket trading as investors reacted to the prospect of a costly and lengthy delay.

In final minutes from a late January meeting, the FDA stated it could not agree that data from uniQure's Phase I/II studies, which used an external control group, provided the primary evidence of effectiveness needed for approval. Instead, the agency strongly recommended the company conduct a prospective, randomized, double-blind, sham surgery-controlled study—a high bar for clinical evidence that will push the therapy's potential launch back by years.

A Higher Bar for Approval

The FDA's decision represents a stark reversal from what the company believed was a previously understood path forward. As recently as late 2024, uniQure had announced an apparent alignment with the agency that its ongoing studies, compared against a natural history dataset, could potentially support a Biologics License Application (BLA) under the Accelerated Approval pathway. The therapy had also received both Breakthrough Therapy and Regenerative Medicine Advanced Therapy (RMAT) designations, programs designed to expedite the development of treatments for serious conditions.

However, the agency's final stance underscores the immense challenge of proving efficacy for complex gene therapies delivered directly to the brain. The FDA's feedback highlighted that the Phase I/II study, despite showing some encouraging biomarker trends, failed to demonstrate a sufficient treatment effect compared to sham-treated subjects after 12 months. This lack of clear separation between the treatment and control groups appears to have been a critical factor in the agency’s demand for more robust data.

“While we did not reach alignment on a submission pathway based on the Phase I/II data, we believe the totality and durability of our data warrant continued substantive dialogue regarding how the FDA’s stated commitment to regulatory flexibility may be appropriately applied in this setting,” said Matt Kapusta, chief executive officer at uniQure, in a statement. “We remain committed to engaging with the FDA to determine a clear, scientifically grounded, and efficient path forward for AMT-130.”

The company now plans to request a Type B meeting with the FDA in the second quarter of 2026 to discuss potential designs for the newly required Phase III trial.

Market Reacts as uniQure Regroups

The financial fallout from the FDA's decision was immediate and severe, with uniQure's stock price falling to near its 52-week low. The development introduces significant uncertainty and risk into what was considered one of the company's flagship programs. Despite the setback, however, uniQure appears financially positioned to weather the storm.

As of its latest reporting at the end of 2025, the company held over $622 million in cash and equivalents. Management has stated this provides a financial runway extending into the second half of 2029, giving it the necessary resources to fund a large-scale Phase III trial. This strong cash position is a critical buffer, as the cost and complexity of the trial mandated by the FDA will be substantial.

Analyst reactions were cautious. Stifel, for instance, maintained a “Buy” rating on the stock but acknowledged that a sham-controlled study introduces “meaningful risk.” The FDA's firm position sends a clear signal to the entire gene therapy industry: even for devastating diseases with no other options, the demand for high-quality, unambiguous evidence of effectiveness remains paramount.

The Cost of Certainty: The 'Sham Surgery' Dilemma

The FDA's recommendation for a sham surgery-controlled trial places uniQure and the Huntington's patient community in a difficult position. This type of study is considered the gold standard for eliminating placebo effects in surgical interventions. In this case, it would involve some patients receiving the AMT-130 gene therapy via a neurosurgical procedure, while a control group would undergo a mock surgery—for instance, receiving anesthesia and an incision, and potentially having partial burr holes drilled into the skull, but without the actual therapy being administered.

This approach presents significant ethical and logistical hurdles. Exposing patients to the risks of an invasive procedure without any potential for therapeutic benefit is a major ethical concern. Recruiting patients for such a trial is also exceptionally challenging, as individuals with a fatal, progressive disease must weigh the possibility of undergoing brain surgery for no personal gain against the hope of contributing to science.

However, precedents for such trials exist, particularly in studies for Parkinson's disease. Regulators and researchers argue that for permanent, one-time interventions like gene therapy, the certainty provided by a sham-controlled trial is necessary to ensure that any observed benefits are real and not a result of patient expectation or the natural fluctuations of the disease. The FDA’s demand reflects a belief that for AMT-130, such a trial is not only necessary but feasible.

A Devastating Delay for the Huntington's Community

Beyond the corporate and financial implications, the FDA's decision is a profound disappointment for thousands of patients and families affected by Huntington's disease. HD is a fatal, inherited neurodegenerative disorder that relentlessly strips individuals of their ability to move, think, and function, with no approved treatments that can slow or stop its progression. Current therapies only manage symptoms.

AMT-130, which is designed to lower the mutant huntingtin protein that causes the disease, represented a beacon of hope. Positive, though preliminary, data had generated considerable excitement. Now, that hope is deferred. The delay underscores the urgent and unmet need in the HD community and highlights the brutal realities of drug development.

While uniQure's program faces a new hurdle, other companies continue to pursue different approaches. Roche and Ionis Therapeutics are still assessing data from their ASO therapy, tominersen, after a late-stage trial was halted. Meanwhile, companies like Wave Life Sciences and Prilenia Therapeutics are advancing their own candidates through the clinic. This competitive landscape provides some hope, but also illustrates the immense difficulty of tackling this complex disease. For now, uniQure and the patients who looked to AMT-130 must navigate a longer and more uncertain road as they prepare for the next, more demanding phase of clinical evaluation.